BMS-214662 is primarily investigated for its potential in cancer therapy, particularly as a farnesyltransferase inhibitor. It targets and inhibits the farnesyltransferase enzyme, which plays a crucial role in the activation of certain proteins involved in cancer cell growth and survival. By blocking this enzyme, it disrupts the signaling pathways that promote tumor progression, making it a promising candidate for treating various cancers, including pancreatic and breast cancer. Research is ongoing to explore its efficacy in combination with other therapies to enhance its anticancer effects.